Effect of omega-3 fatty acid on the fatty acid content of the erythrocyte membrane and proteinuria in patients with diabetic nephropathy

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Lee, Su Mi ^a   Chung, Seuk Hee ^b   Park, Yongjin ^a   Park, Mi Kyoung ^a   Son, Young Ki ^a   Kim, Seong Eun ^a   An, Won Suk ^a,c  

^a Dong A University   (South Korea)

^b Central Hospital   (South Korea)

^c Dong A University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; ICOSAPENTAENOIC ACID; OLEIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 84930665073     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/208121     Document Type: Article

References (53)

1. I.H.deBoer, T. C. Rue, Y. N. Hall,P. J.Heagerty, N. S.Weiss, and J. Himmelfarb, "Temporal trends in the prevalence of diabetic kidney disease in the United States," Journal of the American Medical Association, vol. 305, no. 24, pp. 2532-2539, 2011.
2. E. Imai, S. Ito,M.Haneda, J. C. N. Chan, andH.Makino, "Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (orient): Rationale and study design," Hypertension Research, vol. 29, no. 9, pp. 703-709, 2006.
3. D. de Zeeuw, G. Remuzzi, H.-H. Parving et al., "Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL," Kidney International, vol. 65, no. 6, pp. 2309-2320, 2004.
4. H. Shimizu, K.-I. Ohtani, Y. Tanaka, N. Sato, M. Mori, and Y. Shimomura, "Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients," Diabetes Research and Clinical Practice, vol. 28, no. 1, pp. 35-40, 1995.
5. A. V. Möllsten, G. G. Dahlquist, E.-L. Stattin, and S. Rudberg, "Higher intakes of fish protein are related to a lower risk of microalbuminuria in young swedish type 1 diabetic patients," Diabetes Care, vol. 24, no. 5, pp. 805-810, 2001.
6. J. H. Garman, S. Mulroney, M. Manigrasso, E. Flynn, and C. Marie, "Omega-3 fatty acid rich diet prevents diabetic renal disease," American Journal of Physiology-Renal Physiology, vol. 296, no. 2, pp. F306-F316, 2009.
7. A. J. Krentz, G. Clough, and C. D. Byrne, "Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications," Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 781-791, 2007.
8. H. C. Gerstein, J. F. E.Mann, Q. Yi et al., "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals,"The Journal of the American Medical Association, vol. 286, no. 4, pp. 421-426, 2001.
9. M. Svensson, E. B. Schmidt, K. A. Jørgensen, and J. H. Christensen, "N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial," Clinical journal of the American Society of Nephrology, vol. 1, no. 4, pp. 780-786, 2006.
10. F.B.Hu, L. Bronner,W. C.Willett et al., "Fish and omega-3 fatty acid intake and risk of coronary heart disease in women," The Journal of the AmericanMedical Association, vol. 287, no. 14, pp. 1815-1821, 2002.
11. S. M. Lee and W. S. An, "Cardioprotective effects of ω-3 PUFAs in chronic kidney disease," BioMed Research International, vol. 2013, Article ID 712949, 8 pages, 2013.
12. M. L. Burr, A.M. Fehily, J. F. Gilbert et al., "Effects of changes in fat, fish, and fibre intakes on death andmyocardial reinfarction: Diet and reinfarction trial (DART),"TheLancet, vol. 2, no. 8666, pp. 757-761, 1989.
13. R. Marchioli, "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: results of the gissi-prevenzione trial. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico," The Lancet, vol. 354, no. 9177, pp. 447-455, 1999.
14. E. C. Rizos, E. E. Ntzani, and M. S. Elisaf, "Omega-3 fatty acid supplementation and cardiovascular disease events-eply," JAMA-Journal of the American Medical Association, vol. 309, no. 1, p. 29, 2013.
15. J. H. Christensen, H. Aarup Skou, T. Madsen, I.Tørring, and E. Berg Schmidt, "Heart rate variability and n-3 polyunsaturated fatty acids in patients with diabetes mellitus," Journal of Internal Medicine, vol. 249, no. 6, pp. 545-552, 2001.
16. E. N. Siguel and R. H. Lerman, "Altered fatty acid metabolism in patients with angiographically documented coronary artery disease," Metabolism: Clinical and Experimental, vol. 43, no. 8, pp. 982-993, 1994.
17. F. Paganelli, J. M. Maixent, M. J. Duran, R. Parhizgar, G. Pieroni, and S. Sennoune, "Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease," International Journal of Cardiology, vol. 78, no. 1, pp. 27-32, 2001.
18. R. C. Block,W. S.Harris, K. J. Reid, and J. A. Spertus, "Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes?" American Heart Journal, vol. 156, no. 6, pp. 1117-1123, 2008.
19. J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz, "Diabetic nephropathy: diagnosis, prevention, and treatment," Diabetes Care, vol. 28, no. 1, pp. 164-176, 2005.
20. J. S. Oh, S.M. Kim, Y. H. Sin et al., "Comparison of erythrocyte membrane fatty acid contents in renal transplant recipients and dialysis patients," Transplantation Proceedings, vol. 44, no. 10, pp. 2932-2935, 2012.
21. S. Jo, W.-S. An, and Y. Park, "Erythrocyte n-3 polyunsaturated fatty acids and the risk of type 2 diabetes in koreans: a casecontrol study," Annals of Nutrition and Metabolism, vol. 63, no. 4, pp. 283-290, 2014.
22. W. S. An, S.M. Lee, Y. K. Son et al., "Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 86, no. 1-2, pp. 29-34, 2012.
23. W. S. An, S. M. Lee, Y. K. Son et al., "Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients," Nutrition Research, vol. 32, no. 7, pp. 495-502, 2012.
24. S.M.Namayandeh, F. Kaseb, andS.Lesan, "Olive and sesame oil effect on lipid profile in hypercholesterolemic patients, which better?" International Journal of Preventive Medicine, vol. 4, no. 9, pp. 1059-1062, 2013.
25. M. Trevisan, V. Krogh, J. Freudenheim et al., "Consumption of olive oil, butter, and vegetable oils and coronary heart disease risk factors,"The Journal of the American Medical Association, vol. 263, no. 5, pp. 688-692, 1990.
26. M. D. Navarro, J. L. Periago, M. L. Pita, and P. Hortelano, "The n-3 polyunsaturated fatty acid levels in rat tissue lipids increase in response to dietary olive oil relative to sunflower oil," Lipids, vol. 29, no. 12, pp. 845-848, 1994.
27. C. D. Green, C. G. Ozguden-Akkoc, Y. Wang, D. B. Jump, and L. K. Olson, "Role of fatty acid elongases in determination of de novo synthesized monounsaturated fatty acid species," Journal of Lipid Research, vol. 51, no. 7, pp. 1871-1877, 2010.
28. B. A. Perkins, L. H. Ficociello, B. E.Ostrander et al., "Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes," Journal of theAmericanSociety ofNephrology, vol. 18, no. 4, pp. 1353-1361, 2007.
29. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy," The New England Journal of Medicine, vol. 329, no. 20, pp. 1456-1462, 1993.
30. E. J. Lewis, L. G. Hunsicker,W. R. Clarke et al., "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes," The New England Journal of Medicine, vol. 345, no. 12, pp. 851-860, 2001.
31. N. Nakao, A. Yoshimura, H.Morita,M. Takada, T. Kayano, and T. Ideura, "Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial," The Lancet, vol. 361, no. 9352, pp. 117-124, 2003.
32. M. Cortinovis, D. Cattaneo, N. Perico, and G. Remuzzi, "Investigational drugs for diabetic nephropathy," Expert Opinion on Investigational Drugs, vol. 17, no. 10, pp. 1487-1500, 2008.
33. P. Fioretto, M. L. Caramori, and M. Mauer, "The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007," Diabetologia, vol. 51, no. 8, pp. 1347-1355, 2008.
34. U. O. Barcelli, J. Miyata, Y. Ito et al., "Beneficial effects of polyunsaturated fatty acids in partially nephrectomized rats," Prostaglandins, vol. 32, no. 2, pp. 211-219, 1986.
35. W. S. An,H. J. Kim, K.-H. Cho, andN.D. Vaziri, "Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney," American Journal of Physiology-Renal Physiology, vol. 297, no. 4, pp. F895-F903, 2009.
36. F. Lauretani, M.Maggio, F. Pizzarelli et al., "Omega-3 and renal function in older adults," Current Pharmaceutical Design, vol. 15, no. 36, pp. 4149-4156, 2009.
37. J.V.DonadioJr.,T.S.Larson, E. J. Bergstralh, and J. P.Grande, "A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy," Journal of the American Society of Nephrology, vol. 12, no. 4, pp. 791-799, 2001.
38. F. Lauretani, R. D. Semba, S. Bandinelli et al., "Plasma polyunsaturated fatty acids and the decline of renal function," Clinical Chemistry, vol. 54, no. 3, pp. 475-481, 2008.
39. K. Esposito, R. Marfella, M. Ciotola et al., "Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial," The Journal of the AmericanMedical Association, vol. 292, no. 12, pp. 1440-1446, 2004.
40. F. Perez-Jimenez, G. A. de Cienfuegos, L. Badimon et al., "International conference on the healthy effect of virgin olive oil," European Journal of Clinical Investigation, vol. 35, no. 7, pp. 421-424, 2005.
41. C. E. Friedberg, M. J. F. M. Janssen, R. J. Heine, and D. E. Grobbee, "Fish oil and glycemic control in diabetes. A metaanalysis," Diabetes Care, vol. 21, no. 4, pp. 494-500, 1998.
42. V. M.Montori, A. Farmer, P. C.Wollan, and S. F. Dinneen, "Fish oil supplementation in type 2 diabetes: a quantitative systematic review," Diabetes Care, vol. 23, no. 9, pp. 1407-1415, 2000.
43. S.E.Nielsen,K. J. Schjoedt, A. S. Astrup et al., "Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril," DiabeticMedicine, vol. 27, no. 10, pp. 1144-1150, 2010.
44. D. Bolignano, A. Lacquaniti, G. Coppolino et al., "Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease," Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 337-344, 2009.
45. R. C. Harris, "COX-2 and the kidney," Journal of Cardiovascular Pharmacology, vol. 47, supplement 1, pp. S37-S42, 2006.
46. N. O. S. Câmara, J. O. Martins, R. G. Landgraf, and S. Jancar, "Emerging roles for eicosanoids in renal diseases," Current Opinion in Nephrology and Hypertension, vol. 18,no. 1, pp. 21-27, 2009.
47. M. L.McDaniel, G. Kwon, J. R. Hill, C. A. Marshall, and J. A. Corbett, "Cytokines and nitric oxide in islet inflammation and diabetes," Proceedings of the Society for Experimental Biology and Medicine, vol. 211, no. 1, pp. 24-32, 1996.
48. S. J. Persaud, D. Muller, V. D. Belin et al., "The role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans," Diabetes, vol. 56, no. 1, pp. 197-203, 2007.
49. D.Wei, J. Li, M. Shen et al., "Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic β-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death," Diabetes, vol. 59, no. 2, pp. 471-478, 2010.
50. J. Bellenger, S. Bellenger, A. Bataille et al., "High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition," Diabetes, vol. 60, no. 4, pp. 1090-1099, 2011.
51. J. C. Lovejoy, "The influence of dietary fat on insulin resistance," Current Diabetes Reports, vol. 2, no. 5, pp. 435-440, 2002.
52. T. Jafari, A. A. Fallah, and L. Azadbakht, "Role of dietary n-3 polyunsaturated fatty acids in type 2 diabetes: a review of epidemiological and clinical studies," Maturitas, vol. 74, no. 4, pp. 303-308, 2013.
53. J.-S. Zheng, T. Huang, J. Yang, Y.-Q. Fu, and D. Li, "Marine n-3 polyunsaturated fatty acids are inversely associated with risk of type 2 diabetes in asians: a systematic reviewand meta-analysis," PLoS ONE, vol. 7, no. 9,Article ID e44525, 2012.